Carcinoid syndrome medical therapy

Revision as of 17:03, 17 August 2015 by Jyostna Chouturi (talk | contribs)
Jump to navigation Jump to search

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Carcinoid syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Carcinoid Syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Carcinoid syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Carcinoid syndrome medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Carcinoid syndrome medical therapy

CDC on Carcinoid syndrome medical therapy

Carcinoid syndrome medical therapy in the news

Blogs on Carcinoid syndrome medical therapy

Directions to Hospitals Treating Carcinoid syndrome

Risk calculators and risk factors for Carcinoid syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

For symptomatic relief of carcinoid sydromes medical therapy many include: octreotide, methysergide maleate, and cyproheptadine.

Medical Therapy

Symptomatic relief may be provided by any of the following medical therapies:

  • Octreotide (somatostatin analogue- neutralizes serotonin and decreases urinary 5-HIAA)
  • Methysergide maleate (antiserotonin agent but not used because of serious side effect of retroperitoneal fibrosis)
  • Cyproheptadine (antihistamine)

Chemotherapy

Chemotherapy is of little benefit and is generally not indicated. Octreotide (a somatostatin analogue) may decrease the secretory activity of the carcinoid.

References


Template:WikiDoc Sources